AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05184933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circadian Protocol
Description: Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
Study NCT05184933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rested Wakefulness Trial
Description: Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
Study NCT05184933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overnight Sleep Trial
Description: Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
Study NCT05184933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularized Sleep Schedule
Description: All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
Study NCT04989647 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No adjuvant therapy
Description: Patients will not receive any type of adjuvant therapy.
Study NCT04989647 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
Study NCT05169060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil Concentrate, 1000 Mg Oral Capsule
Description: Oral capsules, 2 grams or 4 grams per day.
Study NCT05169060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate Oral Tablet
Description: Oral tablets, 1.5 gram or 3.0 gram per day.
Study NCT04721548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Topical Foam
Description: Apply 1 mL of solution twice a day.
Study NCT04721548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of solution twice a day.
Study NCT05106855 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low Laser Radiation
Description: One group will receive laser application to check if there is acceleration of healing.
Study NCT05106855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Changing the implant surface
Description: Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
Study NCT05106855 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low Laser Radiation off
Description: This group will receive laser application off.
Study NCT05106855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implant placement immediately after tooth extraction
Description: When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
Study NCT05106855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Installing the dental crown with early loading
Description: The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
Study NCT05951530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: this group received conventional upper extremity active ROMs and stretches for 30 minutes three to five times a week for 6 weeks without using the app-based cognitive training.
Study NCT05951530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app-based cognitive training
Description: This group received mobile app-based cognitive training of 30minutes session three to five times a week for 6 weeks which includes a few activities such as the memory, coordination and alertness along with conventional UE exercises for 15 minutes three to five times a week for 6 weeks.
Study NCT05272904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quilting
Description: Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
Study NCT05272904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound closure
Description: Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
Study NCT05473273 — intervention group
Intervention type: DRUG
Intervention: Endometrin 100Mg Vaginal Insert
Description: Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
Study NCT05473273 — intervention group
Intervention type: DRUG
Intervention: Estradiol Valerate
Description: Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
Study NCT06541288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI Prediction Model
Description: Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer. Further pelvic lymph node metastasis status was determined by artificial intelligence multimodal fusion prediction modeling
Study NCT06541288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Imageing Assessment
Description: Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer.Further pelvic MRI images are read by a specialized imaging physician to determine pelvic lymph node status.
Study NCT05152836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation at tremor frequency
Description: Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
Study NCT05152836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation at tremor frequency*1.5
Description: Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
Study NCT05152836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation at continuous stimulation
Description: Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
Study NCT05794698 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
Study NCT04003896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc.
Study NCT05637736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction by Therapeutic VR
Description: Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
Study NCT05637736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Stress Reduction
Description: 39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
Study NCT06581562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Study NCT06581562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Study NCT06581562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Study NCT06581562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Study NCT06581991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)
Description: Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
Study NCT05160740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green for injection
Description: ICG will be injected to participants preoperatively for molecular fluorescence image
Study NCT05160740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine green for injection
Description: ICG will be injected to participants preoperatively for molecular fluorescence image
Study NCT06553352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib combined with Obinutuzumab
Description: Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
Study NCT05387317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Standard dose
Description: Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).
Study NCT05387317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca Standard dose
Description: Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein
Study NCT05387317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Fractional dose
Description: Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).
Study NCT05146648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gondola AMPS
Description: One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
Study NCT05146648 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gondola AMPS
Description: One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
Study NCT04725851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High concentration Oxygen therapy
Description: FiO2 >80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
Study NCT04725851 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control: Room Air or Low concentration Oxygen
Description: FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
Study NCT05387317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca Fractional dose
Description: Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein
Study NCT05152836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation 10% below and above step frequency
Description: This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
Study NCT05387317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Standard dose
Description: Standard dose (50ug in 0.25ml)
Study NCT05387317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Fractional dose
Description: Fractional dose (20ug in 0.1ml)
Study NCT05614375 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic surgery
Description: transnasal endoscopic surgery
Study NCT06322329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic MRI
Description: Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
Study NCT05275647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX 100U in normal saline
Description: LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
Study NCT05331547 — intervention group
Intervention type: DEVICE
Intervention: BioFreedom BA9 (SS) Ultra DCS
Description: BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
Study NCT05441124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfullness Based Stress Reduction (MBSR) intervention
Description: Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
Study NCT05275647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
Study NCT05992597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZR2 RDHAP
Description: ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.